Kairos Pharma Enters Material Definitive Agreement
Ticker: KAPA · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1962011
| Field | Detail |
|---|---|
| Company | Kairos Pharma, LTD. (KAPA) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Kairos Pharma just signed a big deal, filing an 8-K on Oct 7th.
AI Summary
On October 1, 2025, Kairos Pharma, Ltd. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in Los Angeles, CA, filed this 8-K report on October 7, 2025. The filing also indicates other events and includes financial statements and exhibits.
Why It Matters
This filing signals a significant development for Kairos Pharma, potentially impacting its strategic direction and future financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that are not yet fully understood.
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
- October 7, 2025 (date) — Date of report
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Kairos Pharma?
The filing states that Kairos Pharma, Ltd. entered into a material definitive agreement on October 1, 2025, but the specific details of this agreement are not provided in the excerpt.
When was this 8-K report filed with the SEC?
This 8-K report was filed on October 7, 2025.
Where are Kairos Pharma's principal executive offices located?
Kairos Pharma's principal executive offices are located at 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Kairos Pharma, Ltd.
What is the Standard Industrial Classification code for Kairos Pharma?
The Standard Industrial Classification code for Kairos Pharma is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 953 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2025-10-07 08:00:47
Key Financial Figures
- $0 — ch registered Common Stock, par value $0.001, per share KAPA NYSE American
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 23KB
- ex10-2.htm (EX-10.2) — 15KB
- ex99-1.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001493152-25-017208.txt ( ) — 269KB
- kapa-20251001.xsd (EX-101.SCH) — 3KB
- kapa-20251001_lab.xml (EX-101.LAB) — 33KB
- kapa-20251001_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01. Material Agreements
Item 1.01. Material Agreements. On October 1, 2025, the board of directors (the "Board") of Kairos Pharma, Ltd., a Delaware Corporation ("Kairos" or the "Company"), approved the entry of Kairos and its wholly-owned subsidiary, Enviro Therapeutics, Inc. ("Enviro"), into a novation agreement (the "Cedars Novation Agreement") with Cedars-Sinai Medical Center ("Cedars"). The Cedars Novation Agreement was entered into on October 1, 2025, but effective as of April 17, 2025 and was entered into in order to transfer the exclusive license of two patents from Enviro, as the original licensee, to Kairos, as the new licensee. As the new licensee of the two patents, Kairos accepted and assumed all obligations and liabilities that may arise under the exclusive license agreements from Enviro and Enviro is relived of all of its liabilities and obligations under the license agreements. The two patents subject to the Novation Agreement include the "Exclusive License Agreement to the Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial or Genomic DNA from Circulation and for Detection of Mitochondrial or Genomic DNA," originally dated June 2, 2025, as amended to date; and the "Exclusive License Agreement to Sensitization of Tumors to Therapies Through Endoglin Antagonism," originally dated June 2, 2021, as amended to date. In addition, on October 1, 2025, the Board approved the Company's entry into a novation agreement (the "Tracon Novation Agreement") with Tracon Pharmaceuticals, Inc. (the "Tracon") and Enviro pursuant to which Enviro's rights and obligations in the license and supply agreement between Tracon, Enviro and Kairos, originally dated May 21, 2021, as amended to date (the "Tracon License Agreement"), were transferred to Kairos and Enviro was relieved of any further liabilities or obligations under the license and supply agreement. Under the Tracon License Agreement, Tracon had granted Enviro exclusive access to its TRC105 and CD105